National Comprehensive Cancer Network

About NCCN

Researchers Receive $1,886,237 in Funding from NCCN Clinical Trials Network

ROCKLEDGE, PA, February 20, 2003 - The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, is very pleased to announce the awarding of $1,886,237 in research grants provided through the NCCN Clinical Trials Network (CTN).

“NCCN’s Clinical Trials Network, a program devoted to facilitating the development of promising new therapeutics to improve patient outcomes, is very pleased to offer research funding to support investigator-initiated trials,” said Diane Paul, MS, RN, Director, NCCN Clinical Trials Network. “Our research collaboration with Pharmacia Corporation to provide these grants will provide new knowledge and hopefully new options for cancer treatment. ” The NCCN CTN facilitates ready access to nineteen preeminent cancer centers and expedites site identification and initiation.

The following proposals have been awarded funding by the NCCN Scientific Review Committees:

  • P. J. Creaven and Y. M. Rustum, Roswell Park Cancer Institute, “Phase I Study of Irinotecan followed by Capecitabine in Patients with Advanced Breast Carcinoma with Biopsiable Tumor,” Award = $220,000
  • P.T. Ramirez, University of Texas M.D. Anderson Cancer Center, “Phase I Trial of Concurrent Weekly CPT-11, Cisplatinum, and Radiotherapy for Patients with Locally Advanced Cancer of the Uterine Cervix,” Award = $120,000
  • A.F. Badawi and N. L. Lewis, Fox Chase Cancer Center, “A Randomized Trial of Celecoxib +/- Rosiglitazone vs. Placebo in Patients with Early Stage Non-Invasive Bladder Carcinoma,” Award = $99,978
  • M. Hidalgo, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, “Biological Evaluation of Celecoxib in Pancreatic Cancer,” Award = $100,000
  • R. Komaki, University of Texas M. D. Anderson Cancer Center, “Cox-2 Enzyme Inhibitors as Molecular Targeting Strategies in Chemoradiation Therapy of Lung Cancer,” Award = $100,000
  • B. Rini, UCSF Comprehensive Cancer Center, “A Phase II Trial of Celecoxib Plus Interferon in Advanced Renal Cell Carcinoma,” Award = $172,528
  • Y. Rustum and M. Javle, Roswell Park Cancer Institute, “Celecoxib in Combination with Weekly Irinotecan (CPT-11), 5-Fluorouracil and Leucovorin in Patients with Advanced Colorectal Carcinoma. A Phase I, Pharmacokinetic Study,” Award = $150,000
  • M. H. Shah, Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, “Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma,” Award = $150,487
  • C. L. Shapiro, Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, “A Phase II Trial of Exemestane (Aromasin) in Combination with Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women with Stage II, III Breast Cancer: Molecular Correlative Studies,” Award = $98,643
  • P. Twardowski, City of Hope Cancer Center, “Biologic Markers of Angiogenesis: A Companion Study to ‘Phase I Trial of Oral Etoposide in Combination with Celecoxib in Patients with Advanced Malignancies’ and ‘Phase I Trial of Oral Cyclophosphamide in Combination with Celecoxib in Patients with Advanced Malignancies,’” Award = $100,000
  • S. Moulder, H. Lee Moffitt Cancer Center, “A Single Arm Phase II Study of Gemcitabine and Irinotecan in Patients with Metastatic Breast Cancer,” Award = $297,485
  • M. Wasif Saif, University of Alabama at Birmingham Comprehensive Cancer Center, “A Phase I and Pharmacologic Trial of Sequential Administration of Bi-weekly Gemcitabine as a 24-hour IV Infusion followed by Irinotecan as a 24-hour IV Infusion in Adult Cancer Patients,” Award = $199,975
  • C. L. Shapiro, Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, “Phase II Study of Sequentially Administered Mitomycin and Irinotecan in Patients with Refractory Metastatic and Inflammatory Breast Cancers Molecular Correlative Studies,” Award = $77,141

For more information, please contact Diane Paul, MS, RN, Vice President, Oncology Research Program, NCCN Clinical Trials Network at 215.690.0232.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.

The NCCN Member Institutions are:

  • Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center
  • City of Hope Comprehensive Cancer Center
  • Dana-Farber/Brigham and Women's Cancer Center
    Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • Roswell Park Cancer Institute
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • University of Alabama at Birmingham Comprehensive Cancer Center
  • UC San Diego Moores Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Comprehensive Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital